NitroMed: Patience pays off
NitroMed Inc. has waited almost six years for validation of its contention that BiDil, a nitric oxide-donating compound, would show benefit in African-American patients with heart failure. The company was prepared to wait even longer. But that won't be necessary, as last week NTMD halted its Phase III A-HeFT trial after a Data Safety and Monitoring Board (DSMB) and Steering Committee determined it would be unethical to continue the placebo-controlled study based on the significant survival benefit seen in the treatment group.
The data, in combination with new research associating nitric oxide